(Q33385435)

26 July 2017

title

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial (English)

1 reference

26 July 2017

Se-Hoon Lee

8

0 references

Georg A. Bjarnason

object named as

Georg A Bjarnason

5

0 references

Camillo Porta

object named as

Camillo Porta

3

0 references

Patrick Schöffski

12

object named as

Patrick Schöffski

1 reference

26 July 2017

2

Cezary Szczylik

1 reference

26 July 2017

9

John Haanen

1 reference

26 July 2017

Martin E Gore

1

1 reference

26 July 2017

Sergio Bracarda

4

1 reference

26 July 2017

Stéphane Oudard

6

1 reference

26 July 2017

Subramanian Hariharan

7

1 reference

26 July 2017

Daniel Castellano

10

1 reference

26 July 2017

Eduard Vrdoljak

11

1 reference

26 July 2017

Paul Mainwaring

13

1 reference

26 July 2017

Alejandra Nieto

14

1 reference

26 July 2017

Jinyu Yuan

15

1 reference

26 July 2017

Ronald Bukowski

16

1 reference

26 July 2017

publication date

15 July 2009

1 reference

Lancet Oncology Commission

26 July 2017

published in

1 reference

26 July 2017

volume

10

1 reference

26 July 2017

issue

8

1 reference

26 July 2017

page(s)

757-763

1 reference

Global cancer statistics, 2002

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970162-7

7 January 2021

Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970162-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970162-7

1 reference

7 January 2021

Novel approaches in the therapy of metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970162-7

7 January 2021

Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970162-7

7 January 2021

Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970162-7

7 January 2021

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970162-7

7 January 2021

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970162-7

7 January 2021

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970162-7

7 January 2021

Sunitinib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970162-7

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970162-7

7 January 2021

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970162-7

7 January 2021

Distant metastasis of renal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970162-7

7 January 2021

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970162-7

7 January 2021

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970162-7

7 January 2021

Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970162-7

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970162-7

7 January 2021

Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970162-7

7 January 2021

Complete cerebral response with sunitinib for metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970162-7

7 January 2021

Brain metastases in patients with renal cell cancer receiving new targeted treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970162-7

7 January 2021

10.1016/S1470-2045(09)70162-7

Identifiers

DOI

1 reference

26 July 2017

1 reference